Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.75
Bid: 31.50
Ask: 32.00
Change: -0.25 (-0.78%)
Spread: 0.50 (1.587%)
Open: 31.75
High: 31.75
Low: 31.75
Prev. Close: 32.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Investment Officer

11 Jan 2021 07:00

RNS Number : 1572L
Duke Royalty Limited
11 January 2021
 

11 January 2021

 

Duke Royalty Limited

 

("Duke Royalty", "Duke" or the "Company")

 

Appointment of Chief Investment Officer

 

 

Duke Royalty Limited (AIM: DUKE), a provider of capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to announce the senior management appointment of Mr. Peter Madouros as its Chief Investment Officer. Peter has extensive private equity and credit experience and will operate out of Duke's London office. Jim Webster, who has been Chief Investment Officer and a member of Duke's Investment Committee since 2016, will continue to provide his experience, support and leadership as Chair of the Investment Committee.

 

In light of the Company's growing pipeline of opportunities driven by business owners' desires turn to long-term capital solutions, Mr. Madouros' appointment provides Duke Royalty's Investment team with additional expertise, particularly in the European non-bank credit sector and increases capacity for origination and execution of new transactions. Formerly a senior member of the investment team at Pollen Street Capital, Duke Royalty's debt provider, Mr. Madouros has a strong track record of working closely with UK SMEs to assess their needs and structure appropriate capital solutions. He will be responsible for conducting the due diligence and negotiations on prospective investment opportunities, directing the execution of royalty transactions approved by the Duke Royalty board and monitoring royalty investments made by the Company.

 

Prior to his role at Pollen Street Capital, Mr. Madouros served as an investment professional at Moore Capital Management, a multi-strategy hedge fund focused on global financial markets. Mr. Madouros holds a BA from Cornell University, where he graduated Magna cum Laude, and an MBA from Columbia Business School.

 

Neil Johnson, CEO of Duke Royalty, said:

 

"Peter has a deep understanding of our business, having previously been our key point of contact at Pollen Street Capital, so his decision to join Duke Royalty serves as a strong endorsement of our business model and its exciting future growth potential. Peter's career has been spent in the non-bank credit markets, which gives us additional expertise and relationships as we grow Duke Royalty. His UK presence means that he is ideally placed to work closely with our current and future royalty partners to listen to their requirements and evaluate their suitability.

 

"I am excited that we found a person of Peter's calibre to transition from Jim, who has been invaluable in establishing our initial capital and portfolio, as our Chief Investment Officer. Jim has now successfully launched three royalty companies in three countries which today run collectively over $5 billion. We look forward to his continued valuable role as Chair of the Investment Committee."

 

Jim Webster, Chair of Duke Royalty's Investment Committee, said:

 

"I welcome Peter's appointment as Duke expands its diversified portfolio of royalty partners. Peter brings additional leadership and knowledge to a dedicated team of investment professionals which will further deepen Duke's disciplined investment culture."

 

The Investment Committee is now comprised of:

 

Chair

Jim Webster

 

Executive members:

Neil JohnsonCharles Cannon BrookesPeter Madouros

 

Independent members:

Andrew Carragher - Founder and Managing Partner of DW Healthcare PartnersJohn Romeo - Managing Partner and CEO of Oliver Wyman Forum

Justin Cochrane - CEO of Conic Metals

 

 

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Joint Broker)

 

Stephen Keys / Callum Davidson / Julian Morse / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

 

+44 (0) 207 523 8000

Newgate Communications (PR)

Elisabeth Cowell/ Ian Silvera/ Megan Kovach

+44 (0) 20 3757 6880 dukeroyalty@newgatecomms.com

 

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long-term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAPFEFFFFEFA
Date   Source Headline
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.